Factors influencing use of alternating chemotherapy and radiation schedules in small cell lung cancer.
This overview summarizes the theoretical background of alternating chemotherapy and irradiation schedules and their practical application in multimodal treatment protocols. The question whether alternating schedules provide qualitatively better tumour cell kill than individual components used sequentially or alone will only be answered by randomised clinical trials.
Gregor
A
A
Department Clinical Oncology, Western General Hospital, Edinburgh, UK.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000009:adverse effects; D004260:DNA Repair; D004334:Drug Administration Schedule; D004351:Drug Resistance; D006801:Humans; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy / Q000532:radiotherapy; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D009381:Neoplasms, Radiation-Induced / Q000209:etiology; D016609:Neoplasms, Second Primary / Q000209:etiology; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000528:radiation effects; D011832:Radiation Injuries / Q000209:etiology; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D051381:Rats; D015996:Survival Rate